Updated on 2 September 2026
EAD1662 for the treatment of Alopecia
About
EAD1662 is potential therapeutics for Alopecia based on the mechanisms of protecting HFSCs (Hair Follicle Stem Cells) and enhancing the growth of HFSCs.
EADERM is conducting the GLP toxicology studies of EAD1662, and the Phase1 study for Alopecia Areata has planned in Japan for 2028.
We are seeking a partner to develop and commercialize EAD1662 worldwide.
Organisation
Similar opportunities
Investment
- Startup
- Healthcare
- Biotech, Pharma and Cosmetics
Investment
Investment Opportunity: Scale QVITI’s Integrated Neuromodulation Platform Globally
- Expansion
- Healthcare
- Growth and Establishment
- ICT Industry and Services
- Biotech, Pharma and Cosmetics